Floatz logo

Temsirolimus

Hormone-Resistant Prostate Cancer

Roswell Park Cancer InstituteSmall moleculePhase 1/2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hormone-Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
University of California, Davis
Phase 3BB
Abiraterone Acetate
Alliance for Clinical Trials in Oncology
Phase 3BB
Docetaxel
Seattle Institute for Biomedical and Clinical Research
Phase 3BB
Enzalutamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3BB
Casodex
Mayo Clinic
Phase 2B

View all 50 →

Same molecule, other indications

Temsirolimus is also rated in:

gliosarcomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult glioblastomaDormant
BBB
Indicative ·
74 / 100
View asset →
giant cell glioblastomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →